Quoin Pharmaceuticals
QNRX
1 hedge funds and large institutions have $345K invested in Quoin Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$494K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $264K | +$494K | +1 | New |
|
2
Jane Street
New York
| $76K | – | – | – |
|
3
UBS Group
Zurich,
Switzerland
| $3K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $2K | – | – | – |
|
QNRX Hedge Fund Activity: Q3 2016 in Review
1 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q3 2016, worth a combined $345K.
Buyers outnumbered sellers: 1 fund opened new QNRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $494K.
- 1 institutional investor held Quoin Pharmaceuticals (QNRX) as of Q3 2016, up from 0 in Q2 2016.
- Funds reported $345K of Quoin Pharmaceuticals stock for Q3 2016.
- 1 fund opened new Quoin Pharmaceuticals positions in Q3 2016 and 0 closed out, a net change of +1 holder.
- The largest Quoin Pharmaceuticals buyer in Q3 2016 was Sabby Management, an estimated $494K added.
Based on aggregated 13F filings for Q3 2016.